AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP

GSA Capital Partners LLP lowered its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 46.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,274 shares of the biotechnology company’s stock after selling 32,525 shares during the quarter. GSA Capital Partners LLP owned about 0.13% of AnaptysBio worth $1,141,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its holdings in shares of AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after acquiring an additional 822,975 shares during the last quarter. 683 Capital Management LLC boosted its holdings in AnaptysBio by 155.6% in the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the period. Soleus Capital Management L.P. raised its holdings in shares of AnaptysBio by 214.6% during the second quarter. Soleus Capital Management L.P. now owns 321,040 shares of the biotechnology company’s stock worth $7,127,000 after purchasing an additional 218,988 shares during the period. JPMorgan Chase & Co. lifted its position in shares of AnaptysBio by 1,631.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock worth $5,497,000 after buying an additional 233,325 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of AnaptysBio by 2,236.6% in the 3rd quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock worth $5,920,000 after buying an additional 185,053 shares during the last quarter.

AnaptysBio Price Performance

Shares of ANAB stock opened at $54.83 on Thursday. The business has a 50 day simple moving average of $48.42 and a 200 day simple moving average of $36.27. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -19.44 and a beta of 0.35. AnaptysBio, Inc. has a 12-month low of $13.99 and a 12-month high of $57.65.

AnaptysBio declared that its board has initiated a share repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In related news, insider Eric J. Loumeau sold 10,000 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the completion of the transaction, the insider owned 12,835 shares in the company, valued at $693,090. This represents a 43.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Daniel Faga sold 14,281 shares of the business’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $638,503.51. Following the sale, the chief executive officer owned 479,344 shares in the company, valued at $21,431,470.24. This trade represents a 2.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 156,280 shares of company stock valued at $7,254,939. 33.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ANAB shares. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Stifel Nicolaus lowered their target price on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Barclays raised their price target on AnaptysBio from $55.00 to $78.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Truist Financial boosted their price objective on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Finally, UBS Group assumed coverage on AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $66.89.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.